Serious adverse events
|
LCZ696 |
Total |
Valsartan |
Total subjects affected by serious adverse events
|
|
|
|
subjects affected / exposed
|
145 / 295 (49.15%) |
306 / 592 (51.69%) |
161 / 297 (54.21%) |
number of deaths (all causes)
|
28 |
67 |
39 |
number of deaths resulting from adverse events
|
0 |
1 |
1 |
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
|
|
|
|
B-cell lymphoma
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Basal cell carcinoma
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
7 / 592 (1.18%) |
6 / 297 (2.02%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 8 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Benign hepatobiliary neoplasm
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Bladder neoplasm
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Breast cancer recurrent
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Bronchial carcinoma
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
Carcinoid tumour in the large intestine
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Colon cancer
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Colorectal adenoma
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Endometrial cancer
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Lung adenocarcinoma
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Invasive breast carcinoma
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Lung neoplasm
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Lung cancer metastatic
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Endometrial stromal sarcoma
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Follicular lymphoma
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastric cancer
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hepatic neoplasm
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
Lung neoplasm malignant
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
3 / 592 (0.51%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Metastases to peritoneum
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
Metastases to liver
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Metastases to bone
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Meningioma
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Malignant melanoma
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Lymphocytic leukaemia
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Myelodysplastic syndrome
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Prostatic adenoma
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Prostate cancer
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
4 / 592 (0.68%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 4 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Ovarian cancer
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
Oesophageal carcinoma
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Non-Hodgkin's lymphoma
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Neoplasm prostate
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Refractory cytopenia with unilineage dysplasia
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Tonsil cancer
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Squamous cell carcinoma of lung
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Squamous cell carcinoma
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Renal cell carcinoma
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Vascular disorders
|
|
|
|
Aneurysm
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Aortic aneurysm
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Aortic stenosis
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
2 / 592 (0.34%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Circulatory collapse
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
2 / 592 (0.34%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 4 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
Deep vein thrombosis
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Extremity necrosis
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypertension
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
5 / 592 (0.84%) |
5 / 297 (1.68%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 5 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypertensive crisis
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypertensive urgency
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypotension
|
|
|
|
subjects affected / exposed
|
3 / 295 (1.02%) |
8 / 592 (1.35%) |
5 / 297 (1.68%) |
occurrences causally related to treatment / all
|
1 / 3 |
4 / 9 |
3 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Intermittent claudication
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Orthostatic hypotension
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Peripheral ischaemia
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Peripheral arterial occlusive disease
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
4 / 592 (0.68%) |
3 / 297 (1.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 4 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Shock haemorrhagic
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
Vasculitis
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Subclavian artery stenosis
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Venous thrombosis limb
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
General disorders and administration site conditions
|
|
|
|
Chest pain
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
2 / 592 (0.34%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac death
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
Asthenia
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
2 / 592 (0.34%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Generalised oedema
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Fatigue
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Death
|
|
|
|
subjects affected / exposed
|
5 / 295 (1.69%) |
8 / 592 (1.35%) |
3 / 297 (1.01%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 8 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 5 |
0 / 8 |
0 / 3 |
Impaired healing
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
2 / 592 (0.34%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Oedema
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Non-cardiac chest pain
|
|
|
|
subjects affected / exposed
|
8 / 295 (2.71%) |
10 / 592 (1.69%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 8 |
0 / 10 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Multiple organ dysfunction syndrome
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
Systemic inflammatory response syndrome
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Oedema peripheral
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
2 / 592 (0.34%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Sudden death
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
Vascular stent stenosis
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pyrexia
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
2 / 592 (0.34%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Sudden cardiac death
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
2 / 592 (0.34%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
Immune system disorders
|
|
|
|
Allergy to arthropod bite
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Drug hypersensitivity
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Reproductive system and breast disorders
|
|
|
|
Endometrial hyperplasia
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Testicular swelling
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Testicular pain
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Respiratory, thoracic and mediastinal disorders
|
|
|
|
Bronchiectasis
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Asthma
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Acute respiratory failure
|
|
|
|
subjects affected / exposed
|
5 / 295 (1.69%) |
10 / 592 (1.69%) |
5 / 297 (1.68%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 11 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
Central sleep apnoea syndrome
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Chronic obstructive pulmonary disease
|
|
|
|
subjects affected / exposed
|
9 / 295 (3.05%) |
13 / 592 (2.20%) |
4 / 297 (1.35%) |
occurrences causally related to treatment / all
|
0 / 14 |
0 / 19 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
Cough
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Haemoptysis
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Epistaxis
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
4 / 592 (0.68%) |
3 / 297 (1.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 4 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Dyspnoea exertional
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
3 / 592 (0.51%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Dyspnoea
|
|
|
|
subjects affected / exposed
|
3 / 295 (1.02%) |
10 / 592 (1.69%) |
7 / 297 (2.36%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 12 |
0 / 9 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
Hiccups
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypoxia
|
|
|
|
subjects affected / exposed
|
3 / 295 (1.02%) |
4 / 592 (0.68%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 6 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
Hypercapnia
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hydrothorax
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Interstitial lung disease
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pleuritic pain
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pneumothorax
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
Pulmonary alveolar haemorrhage
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Respiratory failure
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
4 / 592 (0.68%) |
3 / 297 (1.01%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 5 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
Pulmonary toxicity
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pulmonary mass
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pulmonary hypertension
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pulmonary embolism
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
5 / 592 (0.84%) |
4 / 297 (1.35%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 5 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
Sleep apnoea syndrome
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Psychiatric disorders
|
|
|
|
Mental status changes
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Investigations
|
|
|
|
Alanine aminotransferase increased
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Angiocardiogram
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Aspartate aminotransferase increased
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Blood creatinine increased
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
2 / 592 (0.34%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
1 / 2 |
1 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Blood glucose increased
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
C-reactive protein increased
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Catheterisation cardiac abnormal
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hepatic enzyme increased
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Haemoglobin decreased
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Coronavirus test positive
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Liver function test increased
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Viral test positive
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
SARS-CoV-2 test positive
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
3 / 592 (0.51%) |
3 / 297 (1.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Procalcitonin increased
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Weight decreased
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Weight increased
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Injury, poisoning and procedural complications
|
|
|
|
Ankle fracture
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
3 / 592 (0.51%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Femoral neck fracture
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
3 / 592 (0.51%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Fall
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
9 / 592 (1.52%) |
7 / 297 (2.36%) |
occurrences causally related to treatment / all
|
0 / 2 |
1 / 9 |
1 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
1 / 1 |
1 / 1 |
Craniocerebral injury
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Concussion
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cervical vertebral fracture
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Brain contusion
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Epicondylitis
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hip fracture
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Head injury
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Haematuria traumatic
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Fractured sacrum
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
1 / 1 |
1 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Foot fracture
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Fibula fracture
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Femur fracture
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
7 / 592 (1.18%) |
5 / 297 (1.68%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 7 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Rib fracture
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
2 / 592 (0.34%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Procedural complication
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Post procedural pulmonary embolism
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Post procedural haemorrhage
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Periprosthetic fracture
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pelvic fracture
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
2 / 592 (0.34%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Road traffic accident
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
Humerus fracture
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
3 / 592 (0.51%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Skin laceration
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Spinal compression fracture
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
2 / 592 (0.34%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 5 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Sternal fracture
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Subdural haematoma
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
2 / 592 (0.34%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Thoracic vertebral fracture
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Transfusion reaction
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Traumatic fracture
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac disorders
|
|
|
|
Acute coronary syndrome
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
2 / 592 (0.34%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
Acute myocardial infarction
|
|
|
|
subjects affected / exposed
|
8 / 295 (2.71%) |
20 / 592 (3.38%) |
12 / 297 (4.04%) |
occurrences causally related to treatment / all
|
0 / 8 |
0 / 21 |
0 / 13 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 3 |
0 / 3 |
Acute left ventricular failure
|
|
|
|
subjects affected / exposed
|
3 / 295 (1.02%) |
4 / 592 (0.68%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 4 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
Acute right ventricular failure
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Arrhythmia
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
3 / 592 (0.51%) |
3 / 297 (1.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
Aortic valve stenosis
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
Angina unstable
|
|
|
|
subjects affected / exposed
|
3 / 295 (1.02%) |
8 / 592 (1.35%) |
5 / 297 (1.68%) |
occurrences causally related to treatment / all
|
0 / 3 |
1 / 8 |
1 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Angina pectoris
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
5 / 592 (0.84%) |
3 / 297 (1.01%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 7 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Atrial fibrillation
|
|
|
|
subjects affected / exposed
|
14 / 295 (4.75%) |
25 / 592 (4.22%) |
11 / 297 (3.70%) |
occurrences causally related to treatment / all
|
1 / 15 |
1 / 28 |
0 / 13 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Atrial flutter
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
3 / 592 (0.51%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Atrioventricular dissociation
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Atrioventricular block complete
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Atrioventricular block
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
3 / 592 (0.51%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Atrial tachycardia
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Bradyarrhythmia
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac failure chronic
|
|
|
|
subjects affected / exposed
|
4 / 295 (1.36%) |
7 / 592 (1.18%) |
3 / 297 (1.01%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 9 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac failure acute
|
|
|
|
subjects affected / exposed
|
5 / 295 (1.69%) |
10 / 592 (1.69%) |
5 / 297 (1.68%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 14 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac failure
|
|
|
|
subjects affected / exposed
|
15 / 295 (5.08%) |
30 / 592 (5.07%) |
15 / 297 (5.05%) |
occurrences causally related to treatment / all
|
1 / 18 |
2 / 38 |
1 / 20 |
deaths causally related to treatment / all
|
0 / 3 |
0 / 6 |
0 / 3 |
Cardiac arrest
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
6 / 592 (1.01%) |
6 / 297 (2.02%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 6 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 3 |
0 / 3 |
Cardiac amyloidosis
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
Bradycardia
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
3 / 592 (0.51%) |
3 / 297 (1.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac failure congestive
|
|
|
|
subjects affected / exposed
|
8 / 295 (2.71%) |
16 / 592 (2.70%) |
8 / 297 (2.69%) |
occurrences causally related to treatment / all
|
0 / 10 |
0 / 20 |
0 / 10 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
Cardiac valve disease
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cardio-respiratory arrest
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
3 / 592 (0.51%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 3 |
0 / 2 |
Cardiogenic shock
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
Cardiovascular insufficiency
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
Chronic left ventricular failure
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
2 / 592 (0.34%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Coronary artery disease
|
|
|
|
subjects affected / exposed
|
7 / 295 (2.37%) |
10 / 592 (1.69%) |
3 / 297 (1.01%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 10 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
Left ventricular failure
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Myocardial infarction
|
|
|
|
subjects affected / exposed
|
3 / 295 (1.02%) |
10 / 592 (1.69%) |
7 / 297 (2.36%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 10 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 7 |
0 / 5 |
Myocardial ischaemia
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pericardial effusion
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Right ventricular failure
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Sinus bradycardia
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Sinus node dysfunction
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Tachyarrhythmia
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Tachycardia
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
1 / 1 |
1 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Ventricular fibrillation
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
Ventricular extrasystoles
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Nervous system disorders
|
|
|
|
Brain stem infarction
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Brain oedema
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
Bell's palsy
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Carotid artery stenosis
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diabetic neuropathy
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Dementia Alzheimer's type
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cerebrovascular accident
|
|
|
|
subjects affected / exposed
|
4 / 295 (1.36%) |
7 / 592 (1.18%) |
3 / 297 (1.01%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 8 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
Cerebellar stroke
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cerebral haemorrhage
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
Cerebral haematoma
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cerebellar haemorrhage
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cerebral infarction
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
2 / 592 (0.34%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Dysarthria
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Encephalopathy
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
2 / 592 (0.34%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Epilepsy
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
3 / 592 (0.51%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Haemorrhage intracranial
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
2 / 592 (0.34%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Haemorrhagic stroke
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
Headache
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Dizziness
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Ischaemic stroke
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
4 / 592 (0.68%) |
3 / 297 (1.01%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 4 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
Lacunar stroke
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hydrocephalus
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Metabolic encephalopathy
|
|
|
|
subjects affected / exposed
|
3 / 295 (1.02%) |
4 / 592 (0.68%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 5 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Presyncope
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Myelopathy
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Intracranial aneurysm
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Somnolence
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Syncope
|
|
|
|
subjects affected / exposed
|
6 / 295 (2.03%) |
11 / 592 (1.86%) |
5 / 297 (1.68%) |
occurrences causally related to treatment / all
|
2 / 9 |
4 / 15 |
2 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Subarachnoid haemorrhage
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Status epilepticus
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Transient ischaemic attack
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
3 / 592 (0.51%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Blood and lymphatic system disorders
|
|
|
|
Anaemia
|
|
|
|
subjects affected / exposed
|
3 / 295 (1.02%) |
9 / 592 (1.52%) |
6 / 297 (2.02%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 11 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Thrombasthenia
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Thrombocytopenia
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Splenic infarction
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Leukocytosis
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Iron deficiency anaemia
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Thrombotic thrombocytopenic purpura
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Ear and labyrinth disorders
|
|
|
|
Vertigo positional
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
2 / 592 (0.34%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Vertigo
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Chondrodermatitis nodularis chronica helicis
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Eye disorders
|
|
|
|
Diabetic retinopathy
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cataract
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
4 / 592 (0.68%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 4 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Retinal degeneration
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Macular degeneration
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Glaucoma
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Epiretinal membrane
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastrointestinal disorders
|
|
|
|
Abdominal pain
|
|
|
|
subjects affected / exposed
|
3 / 295 (1.02%) |
3 / 592 (0.51%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 5 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Abdominal pain upper
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Anal fissure
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Colitis
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Ascites
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
2 / 592 (0.34%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
Faeces discoloured
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diverticulum intestinal haemorrhagic
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diverticular perforation
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diarrhoea
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Colitis ischaemic
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Haemorrhoidal haemorrhage
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastrointestinal inflammation
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastrointestinal ulcer haemorrhage
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Haematemesis
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastrointestinal haemorrhage
|
|
|
|
subjects affected / exposed
|
3 / 295 (1.02%) |
6 / 592 (1.01%) |
3 / 297 (1.01%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 14 |
0 / 11 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
Gastritis
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Melaena
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
2 / 592 (0.34%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Intestinal mass
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Lower gastrointestinal haemorrhage
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
2 / 592 (0.34%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Mesenteric arterial occlusion
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
Intestinal haemorrhage
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Inguinal hernia
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Nausea
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Retroperitoneal haematoma
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Rectal haemorrhage
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pharyngo-oesophageal diverticulum
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pancreatitis acute
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
2 / 592 (0.34%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pancreatitis
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
2 / 592 (0.34%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Mouth haemorrhage
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Small intestinal obstruction
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Upper gastrointestinal haemorrhage
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Umbilical hernia
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
3 / 592 (0.51%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Vomiting
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hepatobiliary disorders
|
|
|
|
Autoimmune hepatitis
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Bile duct stone
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cholangitis
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac cirrhosis
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hepatic cirrhosis
|
|
|
|
subjects affected / exposed
|
4 / 295 (1.36%) |
4 / 592 (0.68%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 4 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
Cholestasis
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cholecystitis
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cholecystitis acute
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hepatic mass
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Jaundice
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Jaundice cholestatic
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Skin and subcutaneous tissue disorders
|
|
|
|
Angioedema
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Eczema
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Renal and urinary disorders
|
|
|
|
Acute kidney injury
|
|
|
|
subjects affected / exposed
|
6 / 295 (2.03%) |
12 / 592 (2.03%) |
6 / 297 (2.02%) |
occurrences causally related to treatment / all
|
1 / 6 |
2 / 12 |
1 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
Bladder mass
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Chronic kidney disease
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
4 / 592 (0.68%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
1 / 2 |
2 / 4 |
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cystitis interstitial
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
2 / 592 (0.34%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diabetic nephropathy
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Dysuria
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Haematuria
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
2 / 592 (0.34%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hydronephrosis
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Prerenal failure
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Bladder tamponade
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Urinary tract disorder
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Urethral stenosis
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Ureterolithiasis
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Renal tubular necrosis
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
1 / 1 |
1 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Renal impairment
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
3 / 592 (0.51%) |
3 / 297 (1.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
2 / 3 |
2 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Renal failure
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
2 / 592 (0.34%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
2 / 2 |
2 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Urinary retention
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Musculoskeletal and connective tissue disorders
|
|
|
|
Arthritis
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
2 / 592 (0.34%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Arthralgia
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
3 / 592 (0.51%) |
3 / 297 (1.01%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Back pain
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
3 / 592 (0.51%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 4 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cervical spinal stenosis
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Femoroacetabular impingement
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gouty arthritis
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Muscular weakness
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Loose body in joint
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Haemarthrosis
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Osteoarthritis
|
|
|
|
subjects affected / exposed
|
6 / 295 (2.03%) |
10 / 592 (1.69%) |
4 / 297 (1.35%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 11 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Plantar fasciitis
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pain in extremity
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
2 / 592 (0.34%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Osteonecrosis
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Rheumatic disorder
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Spinal disorder
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Spinal stenosis
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
3 / 592 (0.51%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Synovitis
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Vertebral foraminal stenosis
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Infections and infestations
|
|
|
|
Abdominal abscess
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Appendicitis
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Bronchitis
|
|
|
|
subjects affected / exposed
|
3 / 295 (1.02%) |
4 / 592 (0.68%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 5 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Bronchitis bacterial
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
COVID-19
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
5 / 592 (0.84%) |
3 / 297 (1.01%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 5 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
COVID-19 pneumonia
|
|
|
|
subjects affected / exposed
|
4 / 295 (1.36%) |
8 / 592 (1.35%) |
4 / 297 (1.35%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 8 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
Candida infection
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Endocarditis bacterial
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diverticulitis
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
2 / 592 (0.34%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Device related infection
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
3 / 592 (0.51%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cystitis
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Chronic sinusitis
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Cellulitis
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Carbuncle
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastroenteritis
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gangrene
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastroenteritis norovirus
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
2 / 592 (0.34%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Enterococcal bacteraemia
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Erysipelas
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
3 / 592 (0.51%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Escherichia urinary tract infection
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Febrile infection
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Kidney infection
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gastroenteritis viral
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Large intestine infection
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Infected skin ulcer
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Infection
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Infective exacerbation of chronic obstructive airways disease
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Influenza
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Orchitis
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Liver abscess
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pneumonia
|
|
|
|
subjects affected / exposed
|
10 / 295 (3.39%) |
19 / 592 (3.21%) |
9 / 297 (3.03%) |
occurrences causally related to treatment / all
|
0 / 14 |
0 / 23 |
0 / 9 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
Lower respiratory tract infection
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Lymphangitis
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Nosocomial infection
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Oral candidiasis
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Sepsis
|
|
|
|
subjects affected / exposed
|
5 / 295 (1.69%) |
10 / 592 (1.69%) |
5 / 297 (1.68%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 10 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
Pneumonia aspiration
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
Septic shock
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
4 / 592 (0.68%) |
2 / 297 (0.67%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 4 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
Post procedural infection
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Psoas abscess
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Pyelonephritis acute
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Respiratory tract infection viral
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Urinary tract infection
|
|
|
|
subjects affected / exposed
|
6 / 295 (2.03%) |
7 / 592 (1.18%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 8 |
0 / 9 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Urinary tract infection bacterial
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Urosepsis
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
2 / 592 (0.34%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Viral infection
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Wound infection
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Staphylococcal sepsis
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Metabolism and nutrition disorders
|
|
|
|
Cachexia
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diabetic ketoacidosis
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Diabetes mellitus
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Dehydration
|
|
|
|
subjects affected / exposed
|
4 / 295 (1.36%) |
5 / 592 (0.84%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 5 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Gout
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypoglycaemia
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
3 / 592 (0.51%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hyperkalaemia
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
5 / 592 (0.84%) |
3 / 297 (1.01%) |
occurrences causally related to treatment / all
|
2 / 2 |
5 / 5 |
3 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hyperglycaemia
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
2 / 592 (0.34%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypokalaemia
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Lactic acidosis
|
|
|
|
subjects affected / exposed
|
2 / 295 (0.68%) |
2 / 592 (0.34%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hyponatraemia
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Hypomagnesaemia
|
|
|
|
subjects affected / exposed
|
1 / 295 (0.34%) |
1 / 592 (0.17%) |
0 / 297 (0.00%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
Metabolic acidosis
|
|
|
|
subjects affected / exposed
|
0 / 295 (0.00%) |
1 / 592 (0.17%) |
1 / 297 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |